<, rb!>
Inquiry hotline:< bb br )< bb br )
Contact person: Manager Liu
Sale of Gleevec in India: Iressa in India:
Functions and Indications:
Chronic myeloid leukemia, gastrointestinal stromal tumors, and imatinib mesylate is the world's first approved signaling inhibitor related to tumorigenesis.
Edit this paragraph Usage and Dosage
Starting dose: For patients in the blast phase and accelerated phase of chronic myelogenous leukemia, the recommended dose of imatinib mesylate is/day; for patients in the chronic phase who have failed interferon therapy , and patients with malignant gastrointestinal stromal tumors that cannot be surgically removed or metastasized, the recommended dose is/day, which is taken orally once a day. It is advisable to take the medicine with meals and drink a large glass of water. As long as it is effective, it should be continued Take. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (, divided administration) in the following cases: disease progression and treatment failed to obtain after at least 3 months Satisfactory hematological response, hematological response achieved disappeared again. The dose must be adjusted in the following circumstances: If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, the drug should be discontinued until the adverse reactions disappear, and then the dose will be adjusted according to the severity of the adverse reactions. Dosage adjustment in case of severe liver toxicity: If the increase in bilirubin exceeds the upper limit of the normal range or the increase in transaminases exceeds the upper limit of the normal range, the drug should be discontinued until the above indicators drop to or below the upper limit of the normal range respectively. Dose adjustment in the event of neutropenia or thrombocytopenia: Acceleration phase or blast phase: If severe neutropenia and thrombocytopenia occur (neutrophils less than / and / or platelets less than / / day), it is recommended that the dose be reduced to / day. If the blood cells continue to decrease for weeks, the dose should be further reduced to /day. If the blood cells continue to decrease for weeks, it is advisable to stop the drug until neutrophils / and platelets /. The dose when re-used is / day. Patients in the chronic phase after interferon treatment failure: It is advisable to stop taking the drug when the neutrophils are less than / and / or the platelets are less than / /, and then resume the drug only when the neutrophils / and platelets are less than / / day. If the neutrophils or platelets are reduced to the above values again, When resuming the drug, reduce the dose to /day. Children and Adolescents: There are no clinical data on the safety and efficacy of imatinib mesylate treatment in patients under the age of 15. Dosage in patients with liver failure: Patients with hepatic impairment A The plasma concentration of imatinib mesylate can increase, so these patients should be cautious when using this drug. There are currently no clinical data on the use of imatinib mesylate in patients with liver damage, and no dosage adjustment recommendations can be made. Kidney Dosage in Impaired and Elderly Patients: Creatinine clearance is known to decrease with age, and age has no significant effect on the pharmacokinetics of imatinib mesylate, as it has not been clinically studied in patients with renal impairment. Trial, so no dosage adjustment recommendations can be made.
< __ br , r />